Alan P. Graves

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations

Ezh2 Inhibition, Lymphoid Neoplasia, Hematological Malignancy +10

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

Michael T. McCabe, Alan P. Graves, Gopinath Ganji et al. · Proceedings of the National Academy of Sciences · 2012 · 481 citations · Full text

Histone Modifications, Epigenetic Change, Pathology +20

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma, Xinrong Tian, Louis V. LaFrance et al. · ACS Medicinal Chemistry Letters · 2012 · 373 citations · Full text

Histone Modifications, Drug Discovery Program, Engineering +18

Predicting Absolute Ligand Binding Free Energies to a Simple Model Site

David L. Mobley, Alan P. Graves, John D. Chodera et al. · Journal of Molecular Biology · 2007 · 318 citations · Full text

Biochemistry, Natural Sciences, Medicine +8

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9